Nanobiotix Shares Surge 19% at Opening, Extending Bullish Streak

The stock of the French biotech company opened at 21.80 euros this morning, marking a 19% increase from the previous close of 18.22 euros. This rise is part of a remarkable trend across multiple time frames: +22% over the past week, +389.2% over three months, and +350% over the past year, performances that starkly contrast with the +5.96% of the CAC 40 over twelve months. Trading volumes accounted for 1.16% of the capital, demonstrating sustained investor interest in this stock, which is now trading well above its 50-day (9.23 euros) and 200-day (4.98 euros) moving averages.

This latest surge follows the October 1st announcements regarding the initial results of a Phase 1 study evaluating JNJ-1900 in the treatment of esophageal cancer. The reported data showed an 85% disease control rate and a 69% objective response rate, results that also led Jefferies to raise its price target to 21 euros while reaffirming its buy recommendation. The analysis firm acknowledges that the stock has significantly outperformed since the beginning of the year but believes it still has upside potential.

From a technical standpoint, the Relative Strength Index (RSI) has reached 86, a level indicating a pronounced overbought condition and suggesting a possible pause in the short-term progression. The MACD, a momentum indicator, shows positive signals with a main line at 2.58 above its signal line at 1.95, confirming the ongoing bullish momentum. The monthly volatility of 31.16% reflects the magnitude of recent movements, while a beta coefficient of 0.43 indicates moderate sensitivity to overall market fluctuations. The price is now trading above the upper Bollinger band (19.66 euros), a configuration that demonstrates the strength of the bullish movement but may also signal a technical extension.